Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other CancersThomas M. Cardillo, David M. Goldenberg, Roberto Arrojo et al.|Bioconjugate Chemistry|2015Cited by 302
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancerThomas M. Cardillo, David M. Goldenberg, Diane L. Rossi et al.|Oncotarget|2020Cited by 56